Circulation:G蛋白偶联受体自身抗体对体位性直立性心动过速综合征的意义

2022-06-30 MedSci原创 MedSci原创

POTS患者和健康对照组在心血管G蛋白偶联受体自身抗体浓度上没有差异。这些研究结果表明检测这些已知的自身免疫抗体在POTS的诊断中并无价值。

体位性直立性心动过速综合征(POTS)是一种直立性不耐受性疾病,并且主要影响育龄期妇女。POTS的特征是站立后10分钟内出现直立性心动过速(≥30 bpm),且无直立性低血压(≥20/10 mmHg),直立时症状加重,平卧时症状改善。POTS潜在的病理生理机制尚不完全清楚,但已有证据表明自身免疫可能发挥作用。

近日,心血管领域权威杂志Circulation上发表了一篇研究文章,该研究的目的是比较POTS患者和健康对照者之间心血管G蛋白偶联受体自身抗体的浓度。

研究人员收集了来自加拿大卡尔加里和瑞典Malmö的116例POTS患者(91%为女性;平均年龄为29岁)和81名健康对照者(84%为女性;平均年龄为27岁)的血清样本。研究人员使用市售的酶联免疫吸附试验检测了样本中11种受体(肾上腺素能、毒蕈碱、血管紧张素II和内皮素等受体)的自身抗体水平。

研究人员发现针对所有检测受体的自身抗体浓度在对照组和POTS患者之间没有显著差异。大多数POTS患者(98.3%)和所有对照者(100%)的α1肾上腺素能受体自身抗体浓度高于制造商提供的血清阳性阈值(7单位/mL)。对于任何检测的自身抗体,POTS患者与健康对照组低于诊断阈值的比例没有差异。受试者工作特征曲线显示,区分POTS患者和对照组患者的能力较差。

由此可见,POTS患者和健康对照组在心血管G蛋白偶联受体自身抗体浓度上没有差异。这些研究结果表明检测这些已知的自身免疫抗体在POTS的诊断中并无价值。

原始出处:

Juliette Hall,et al.Detection of G Protein–Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome Using Standard Methodology.Circulation.2022.https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059971

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715532, encodeId=3cc41e1553277, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Fri Nov 25 06:31:25 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746947, encodeId=98971e4694779, content=<a href='/topic/show?id=165b836349' target=_blank style='color:#2F92EE;'>#G蛋白偶联受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8363, encryptionId=165b836349, topicName=G蛋白偶联受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=601235881674, createdName=huiwelcome, createdTime=Tue Oct 11 09:31:25 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811545, encodeId=5e8218115457b, content=<a href='/topic/show?id=552688630bf' target=_blank style='color:#2F92EE;'>#蛋白偶联#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88630, encryptionId=552688630bf, topicName=蛋白偶联)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Oct 16 23:31:25 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432338, encodeId=b5d4143233849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471154, encodeId=a17d14e115459, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1715532, encodeId=3cc41e1553277, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Fri Nov 25 06:31:25 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746947, encodeId=98971e4694779, content=<a href='/topic/show?id=165b836349' target=_blank style='color:#2F92EE;'>#G蛋白偶联受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8363, encryptionId=165b836349, topicName=G蛋白偶联受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=601235881674, createdName=huiwelcome, createdTime=Tue Oct 11 09:31:25 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811545, encodeId=5e8218115457b, content=<a href='/topic/show?id=552688630bf' target=_blank style='color:#2F92EE;'>#蛋白偶联#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88630, encryptionId=552688630bf, topicName=蛋白偶联)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Oct 16 23:31:25 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432338, encodeId=b5d4143233849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471154, encodeId=a17d14e115459, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1715532, encodeId=3cc41e1553277, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Fri Nov 25 06:31:25 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746947, encodeId=98971e4694779, content=<a href='/topic/show?id=165b836349' target=_blank style='color:#2F92EE;'>#G蛋白偶联受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8363, encryptionId=165b836349, topicName=G蛋白偶联受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=601235881674, createdName=huiwelcome, createdTime=Tue Oct 11 09:31:25 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811545, encodeId=5e8218115457b, content=<a href='/topic/show?id=552688630bf' target=_blank style='color:#2F92EE;'>#蛋白偶联#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88630, encryptionId=552688630bf, topicName=蛋白偶联)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Oct 16 23:31:25 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432338, encodeId=b5d4143233849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471154, encodeId=a17d14e115459, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1715532, encodeId=3cc41e1553277, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Fri Nov 25 06:31:25 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746947, encodeId=98971e4694779, content=<a href='/topic/show?id=165b836349' target=_blank style='color:#2F92EE;'>#G蛋白偶联受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8363, encryptionId=165b836349, topicName=G蛋白偶联受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=601235881674, createdName=huiwelcome, createdTime=Tue Oct 11 09:31:25 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811545, encodeId=5e8218115457b, content=<a href='/topic/show?id=552688630bf' target=_blank style='color:#2F92EE;'>#蛋白偶联#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88630, encryptionId=552688630bf, topicName=蛋白偶联)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Oct 16 23:31:25 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432338, encodeId=b5d4143233849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471154, encodeId=a17d14e115459, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1715532, encodeId=3cc41e1553277, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Fri Nov 25 06:31:25 CST 2022, time=2022-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746947, encodeId=98971e4694779, content=<a href='/topic/show?id=165b836349' target=_blank style='color:#2F92EE;'>#G蛋白偶联受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8363, encryptionId=165b836349, topicName=G蛋白偶联受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=601235881674, createdName=huiwelcome, createdTime=Tue Oct 11 09:31:25 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811545, encodeId=5e8218115457b, content=<a href='/topic/show?id=552688630bf' target=_blank style='color:#2F92EE;'>#蛋白偶联#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88630, encryptionId=552688630bf, topicName=蛋白偶联)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sun Oct 16 23:31:25 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432338, encodeId=b5d4143233849, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471154, encodeId=a17d14e115459, content=<a href='/topic/show?id=f06c5090466' target=_blank style='color:#2F92EE;'>#心动过速#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50904, encryptionId=f06c5090466, topicName=心动过速)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35817104001, createdName=fengyi814, createdTime=Fri Jul 01 10:31:25 CST 2022, time=2022-07-01, status=1, ipAttribution=)]

相关资讯

JNNP:TRIM46自身抗体相关神经系统副肿瘤综合征的表征

研究最初在一名副肿瘤性脑脊髓炎和小细胞肺癌 (SCLC) 患者中描述了含有三联基序的蛋白 46 (TRIM46) IgG 染色模式。 后来使用免疫沉淀质谱法鉴定了自身抗原。 另外两个随后报告了病例,其

欧洲药理学杂志 :组织蛋白酶 S 抑制剂 ASP1617 作为系统性红斑狼疮治疗的潜在益处

组织蛋白酶 S 抑制剂( CatS )可能是治疗 SLE 的的靶点。

Science Advances:用癌症患者自身抗体生成双抗,用于清除肿瘤

通过将患者自身的特异性抗体与双特异性抗体的效力相结合,利用免疫系统将肿瘤识别为外来物先天能力,创造出一种对肿瘤有效的真正个性化疗法。

ARD:针对 1 型血管紧张素受体的诱导抗体会引发跨物种的皮肤和肺部炎症以及真皮纤维化

该研究的免疫策略诱导了血管紧张素受体1型(AT1R)自身抗体 (Abs),通过激活AT1R促进炎症,并可能导致纤维化。因此,AT1R Abs是未来治疗SSc和其他AT1R Ab相关疾病的有价值的靶点。

Lancet rheumatology:儿童多系统炎症综合征中针对白细胞介素-1受体拮抗剂的自身抗体:一项多中心、回顾性、队列研究

在高比例的儿童多系统炎症综合征(MIS-C)患者中观察到抗IL-1Ra自身抗体,并且对这些患者具有特异性。这些自身抗体的产生可能是由一种非典型的、过度磷酸化的IL-1Ra异构体触发的。

Neurology:胶质纤维酸性蛋白(GFAP)抗体阳性患者的临床特征:一项法国队列研究

GFAP自身免疫主要与伴有前驱症状的急性/亚急性脑膜脑脊髓炎有关,肿瘤和T细胞功能障碍是其常见的触发因素。大多数患者遵循单相疗程,结果良好。